It is printed in the A4 size.To the laboratory site

 - Clinical Medicine (Core Departments) - Internal Medicine
The mission of scientists in the Section of Nephrology is to provide the highest level of patient care, and to conduct basic laboratory and clinical research. Using the latest techniques in biomedical science, molecular biology, immunology, cell biology, knockout mice and iPS cells, researchers investigate the pathophysiology of kidney disease; function of key molecules; effects of many medicines; the cause and treatment of interstitial fibrosis; regeneration of kidney; and the development of new and improved methods to diagnose glomerulosclerosis.

  Motoko Yanagita
Research and Education
Basic research is now mainly focused on tubulo-interstitial injury, diabetic nephropathy, and regeneration of kidney.

i) Novel strategy for the treatment of advanced renal injuries:
Tubular damage is a final common pathway leading to end-stage renal disease. Although the administration of bone morphogenetic protein-7 (BMP-7) has been shown to repair established tubular injuries its pathophysiological role remains elusive. We have recently shown that uterine sensitization-associated gene-1 (USAG-1), novel BMP antagonist abundantly expressed in the kidney, is the central negative regulator of BMP function in the kidney. Inhibition of USAG-1 will be promising means of development of novel treatment for kidney diseases.

ii) Mechanism of the development of diabetic glomerulosclerosis (collaborative research with University of Tokushima): Diabetic nephropathy is characterized by the accumulation of extra-cellular matrix in glomeruli. To elucidate these mechanisms, we examine the role of Smad1 for the progression of diabetic nephropathy, which is the transcriptional factor we reported to directly regulate the expression of type IV collagen, the main component of extra-cellular matrix in sclerotic glomeruli.

iii) Regeneration of kidney:
We also cooperate with the Kidney regeneration group in CiRA (Kenji Osafune’s lab), focusing on the in vitro regeneration of kidney from human iPS cells for transplantation and development of new therapeutic drugs against renal diseases.

In clinical researches, many studies are going on by clinical fellows, such as the beneficial effect of anti-hypertensive drug on renal hemodynamics, the combined effect of cyclosporin and prednisolone for minimal change nephrotic syndrome, the iron metabolism in Japanese hemodialysis patients, and the role of osteocalcin in CKD-MBD patients. Lastly, to provide the highest level of patient care, we continue to educate and train clinical fellows for developing and acquiring expertise as subspecialists in the field of clinical nephrology.

Professor Motoko Yanagita

Tatsuo Tsukamoto

Noriyuki Iehara,
Takeshi Matsubara
Program-Specific Assistant Professor:   Hitomi Miyata
Assistant Professor (Hospital):     Shuichiro Endo
TEL +81-75-751-3860
FAX +81-75-751-3859
Recent Publications
1. Nariaki Asada, Masayuki Takase, Jin Nakamura, Akiko Oguchi, Misako Asada, Norio Suzuki, Ken-ichi Yamamura, Narihito Nagoshi, Shinsuke Shibata, Tata Nageswara Rao, Hans Joerg Fehling, Atsushi Fukatsu, Naoko Minegishi, Toru Kita, Takeshi Kimura, Hideyuki Okano, Masayuki Yamamoto, and Motoko Yanagita
Dysfunction of fibroblasts of extra-renal origin underlies renal fibrosis and renal anemia in mice
J Clin Invest. 121(10):3981-90, 2011
2. Mari Tanaka, Misako Asada, Atsuko Y Higashi, Jin Nakamura, Akiko Oguchi, Mayumi Tomita, Sachiko Yamada, Nariaki Asada, Masayuki Takase, Tomohiko Okuda, Hiroshi Kawachi, Aris N. Economides, Elizabeth Robertson, Satoru Takahashi, Takeshi Sakurai, Roel Goldschmeding, Eri Muso, Atsushi Fukatsu, Toru Kita, and Motoko Yanagita
Loss of the BMP antagonist, USAG-1 ameliorates disease in a mouse model of progressive hereditary kidney disease Alport syndrome
J Clin Invest. 120 (3):768-77, 2010
3. Atsuko Y. Higashi, Tomokatsu Ikawa, Masamichi Muramatsu, Aris N. Economides, Akira Niwa, Tomohiko Okuda, Andrew J. Murphy, Jose Rojas, Toshio Heike, Tatsutoshi Nakahata, Hiroshi Kawamoto, Toru Kita, and Motoko Yanagita
Direct hematological toxicity and illegitimate chromosomal recombination caused by the systemic activation of CreERT2
J Immunol. 182 (9):5633-40, 2009. 
4. Mari Tanaka, Shuichiro Endo, Tomohiko Okuda, Aris N. Economides, David M. Valenzuela, Andrew J. Murphy, Elizabeth Robertson, Takeshi Sakurai, Atsushi Fukatsu, George D. Yancopoulos, Toru Kita, Motoko Yanagita
Expression of BMP-7 and USAG-1 (a BMP antagonist) in kidney development and injury
Kidney Int. 73(2):181-91, 2008.
5. Motoko Yanagita, Shuichiro Endo, Katsu Takahashi, Tomohiko Okuda, Fumihiro Sugiyama, Satoshi Kunita, Satoru Takahashi, Atsushi Fukatsu, Toru Kita, Takeshi Sakurai
USAG-1, a novel BMP antagonist abundantly expressed in the kidney, accelerates kidney injuries.
J Clin Invest. 116: 70-9, 2006.